Thalidomide therapy of cutaneous lupus erythematosus;Thalidomid-therapie des kutanen lupus erythematodes

Hautarzt

Volumn 53, Issue 11, 2002, Pages 744-748

  Bohmeyer, J ^a   Achenbach, A ^a   Westenberger, M ^a   Stadler, R ^a  

^a KLINIKUM MINDEN   (Germany)

Author keywords

Subacute cutaneous lupus erythematosus; Thalidomide

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CHLOROQUINE; CORTICOSTEROID; DNA ANTIBODY; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; THALIDOMIDE;

ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOPENIA; LUPUS ERYTHEMATOSUS; RASH; SIDE EFFECT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; TERATOGENICITY; TREATMENT OUTCOME;

ADULT; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRADERMAL TESTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; PATCH TESTS; PREDNISOLONE; THALIDOMIDE;

EID: 0036943402     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050100227     Document Type: Article

References (15)

1. Collabrese L, Fleischer AB (2000) Thalidomide: current potential clinical applications. Am J Med 108:487-495
2. Calderon P, Anzilotti M, Phelps R (1997) Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 36:881-887
3. Duong DJ, Spigel GT, Moxley RT, Gaspari AA (1998) American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermreatol 135:1079-1087
4. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN (2000) Experience with low-dose thalidomide therpy in chronic discoid lupus erythemaosus. Int J Dermatol 39:218-222
5. Nasca MR, O'Toole EA, Palicharla P, West DP, Woodley DT (1999) Thalidomide increases human kerationocyte migration and proliferation.J Invest Dermatol 113:720-724
6. Ochonisky S, Revuz J (1994) Thalidomide use in dermatology. Eur J Dermatol 4:9-15
7. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S,Vilardell M (2000) Tahlidomide in the tratment of cutaneous lupus refractory to conventional therapy. J Rheumato1 27:1429-1433
8. Raje N, Anderson K (1999) Thalidomide - a revival story. N Engl J Med 341:1606-1609
9. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibts tumor necrosis factor production by stimulted human monocytes. J Exp Med 173:699-703
10. Sato EI,Assis LS, Lourenzi VP, Andrade LE (1998) Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 44:289-293
11. Stevens RJ, Andujar C, Edwards CJ,Ames PR, Barwick AR, Khamshta MA, Hughes GR (1997) Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus experience in sexteen consecutive patients. Br J Rheumtol 36:353-359
12. Stirling DI (1998) Thalidomidean its impact in dermatology. Semin Cutan Med Surg 17:231-242
13. Walchner M, Meurer M, Plewig G, Messer G (2000) Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 39:383-388
14. Warren KJ, Nopper AJ, Crosby DL (1998) Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erthematosus. J Am Acad Dermatol 39:293-29S
15. Zwingenberger K,Wnendt S (1996) Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J Inflamm 46:177-211